BT-001 plus pembrolizumab for localized pMMR rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this Phase 1 study, patients with localized pMMR rectal cancer will receive BT-001 followed by the PD-1 blocker pembrolizumab to assess safety and tolerability of the combination. Eligibility requires appropriate surgical candidacy, confirmed pMMR status, and fit overall health, with specific blood and organ function criteria. The trial aims to see if the viral therapy can modulate the tumor environment to potentially enhance immunotherapy efficacy. No neoadjuvant therapy is required, and treatment precedes or accompanies planned curative resection as clinically indicated. Outcomes will focus on safety signals, tolerability, and preliminary activity to inform future studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological diagnosis of primary, localised rectal adenocarcinoma (cT2N0M0 to cT3bN2M0, TNM classification version 8
* Diagnosis of Proficient Mismatch Repair (pMMR) rectal adenocarcinoma (using biopsy from the initial diagnostic endoscopy)
* Suitable for potentially curative surgical resection
* No contraindications for treatment with pembrolizumab
* Not requiring neoadjuvant therapy
* Aged \> 18 years at the time of inclusion
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Have baseline laboratory results as follows:

  * Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
  * Platelets ≥ 100 ×109/L (without platelet transfusion)
  * Haemoglobin ≥ 6.2 mmol/L or 10.0 g/dL (with or without red blood cell (RBC) transfusion)
  * Serum creatinine ≤ 1.5 × upper limit of normal (ULN)
  * Bilirubin \< 1.5 × ULN (or \< 2.5 x ULN in patients with Gilbert's syndrome)
  * ALT, AST and alkaline phosphatase \< 3 × ULN
* Provide written informed consent in accordance with all applicable regulations and follow the study procedures. Subjects must be capable of understanding the investigational nature, potential risks, and benefits of the study.

Exclusion Criteria:

* Have impending bowel obstruction or other indications for acute surgical intervention
* Have had concurrent immunotherapy in the 3 months before the start of the study therapy.
* Have acute or chronic hepatitis B or hepatitis C infection
* Evidence of immunosuppression for any reason:

  * Known HIV disease
  * Chronic oral or systemic steroid medication use at a dose of \> 10 mg/day of prednisolone or equivalent
  * Other signs or symptoms of clinical immune system suppression
* Have an autoimmune disorder (except thyroiditis with replacement therapy and type I diabetes mellitus)
* Have a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
* Ongoing antiviral therapy active on vaccinia virus, e.g., ribavirin, cidofovir, interferon/ pegylated interferon
* History of severe exfoliative skin conditions (e.g., eczema or atopic dermatitis) requiring systemic therapy for more than 4 weeks within 2 years prior to BT-001 initiation
* Live virus vaccination within 28 days of BT-001 administration
* A history of hypersensitivity to egg or to any excipient of BT-001
* Pregnant or breast-feeding female. Confirmation that women of childbearing potential are not pregnant with a negative serum β-human chorionic gonadotrophin (β-hCG) pregnancy test results must be obtained within 7 days prior to the 1st administration of BT-001
* Fertile males and females who are unwilling to employ highly effective means of contraception during study treatment and for 4 months after the last dose of study treatment

Where it's running

• Copenhagen University Hospital - Bispebjerg and Frederiksberg
  Copenhagen, Captial Region, Denmark Recruiting

Study contacts

• Study coordinator: Henry G Smith, PhD
• Email: henry.george.smith@regionh.dk
• Phone: +4521701936

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer

  This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07898865

• PPISR for low- to mid-rectal cancer with anus-sparing aim

  This study tests whether Precision Partial Intersphincteric Resection can be safely used to remove certain rectal cancers while preserving the anus.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07849023

• Transanal vs Robotic Total Mesorectal Excision for Low Rectal Cancer

  This study tests whether taTME or robot-assisted TME works better for low rectal cancer patients and whether one method leads to fewer complications or conversions.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07651553

• Gynecological and sexual aftereffects following rectal cancer treatment

  This work will test whether gynecological anatomical changes after rectal cancer treatment are linked to ongoing sexual problems in women aged 18–60 who are in remission.

  Recruiting University Hospital, Rouen · Rouen · NCT07389863

• Selective completion total mesorectal excision guided by intra-operative frozen pathology after local excision for low rectal cancer

  This trial tests whether using an immediate frozen-pathology result after local excision to decide if a full total mesorectal excision is needed can keep cancer controlled for adults with low rectal cancer who had a near-complete or small residual response to preoperative chemoradiotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guanggong · NCT07337811

• Radiotherapy Plus CAPOX and Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

  This trial tests whether adding immunotherapy with chemotherapy and radiotherapy before surgery can improve how well locally advanced rectal cancer responds.

  Recruiting Phase 2 Zhongnan Hospital · Wuhan, Hubei · NCT07291401

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.